Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6

Lancet Infect Dis. 2023 Oct;23(10):e397-e398. doi: 10.1016/S1473-3099(23)00555-8. Epub 2023 Sep 11.

Authors

Affiliations

¹ Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
² Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
³ Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.
⁴ Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Electronic address: dh2994@cumc.columbia.edu.

PMID: 37708906
DOI: 10.1016/S1473-3099(23)00555-8

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / therapeutic use
Antibodies, Viral
COVID-19*
Humans
Immunoglobulins
SARS-CoV-2*

Substances

Immunoglobulins
Antibodies, Viral
Antibodies, Neutralizing